ELI LILLY & CO (LLY)

US5324571083 - Common Stock

749.92  -3.49 (-0.46%)

After market: 749.92 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ELI LILLY & CO

NYSE:LLY (11/21/2024, 4:23:02 PM)

After market: 749.92 0 (0%)

749.92

-3.49 (-0.46%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-7.12%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap711.91B
Shares
PE73.74
Fwd PE32.38
Dividend Yield0.66%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

LLY Daily chart

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 43,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The firm manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.

Company Info

ELI LILLY & CO

Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr

Indianapolis INDIANA 46285

P: 13172762000

CEO: David A. Ricks

Employees: 43000

Website: https://www.lilly.com/

LLY News

News Image5 hours ago - Market News VideoLLY January 2025 Options Begin Trading
News Image7 hours ago - The Motley FoolIs Now a Good Time to Buy the Dip in Eli Lilly Stock?

Shares of Lilly are cratering, but investors may be surprised to learn what's influencing the volatility.

ChartMill News Imagea day ago - ChartmillStay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.

Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

News Imagea day ago - QuartzWeight loss drug makers want more insurance plans to cover Wegovy and Zepbound

Novo Nordisk and its rival Eli Lilly are visiting HR teams and labor unions across the country to make the case for anti-obesity drugs

News Imagea day ago - The Motley FoolIs It Time to Sell Eli Lilly and Pfizer Stocks?
News Imagea day ago - Verge GenomicsVerge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS

LLY Twits

Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example